Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
World J Gastroenterol ; 28(11): 1088-1101, 2022 Mar 21.
Article in English | MEDLINE | ID: mdl-35431504

ABSTRACT

Pancreatic cancer is a disease with high unmet clinical need. Pancreatic cancer is also characterised by an intense fibrotic stroma, which harbours many immune cells. Studies in both human and animal models have demonstrated that the immune system plays a crucial role in modulating tumour onset and progression. In human pancreatic ductal adenocarcinoma, high B-cell infiltration correlates with better patient survival. Hence, B cells have received recent interest in pancreatic cancer as potential therapeutic targets. However, the data on the role of B cells in murine models is unclear as it is dependent on the pancreatic cancer model used to study. Nevertheless, it appears that B cells do organise along with other immune cells such as a network of follicular dendritic cells (DCs), surrounded by T cells and DCs to form tertiary lymphoid structures (TLS). TLS are increasingly recognised as sites for antigen presentation, T-cell activation, B-cell maturation and differentiation in plasma cells. In this review we dissect the role of B cells and provide directions for future studies to harness the role of B cells in treatment of human pancreatic cancer.


Subject(s)
Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Tertiary Lymphoid Structures , Animals , Carcinoma, Pancreatic Ductal/pathology , Humans , Mice , Pancreatic Neoplasms/pathology , Tertiary Lymphoid Structures/pathology , Tumor Microenvironment , Pancreatic Neoplasms
2.
World J Gastroenterol ; 27(24): 3483-3501, 2021 Jun 28.
Article in English | MEDLINE | ID: mdl-34239264

ABSTRACT

Pancreatic cancer remains one of medicine's largest areas of unmet need. With five-year survival rates of < 8%, little improvement has been made in the last 50 years. Typically presenting with advance stage disease, treatment options are limited. To date, surgery remains the only potentially curative option, however, with such late disease presentation, the majority of patients are unresectable. Thus, new therapeutic options and a greater understanding of the complex stromal interactions within the tumour microenvironment are sorely needed to revise the dismal outlook for pancreatic cancer patients. Natural killer (NK) cells are crucial effector units in cancer immunosurveillance. Often used as a prognostic biomarker in a range of malignancies, NK cells have received much attention as an attractive target for immunotherapies, both as cell therapy and as a pharmaceutical target. Despite this interest, the role of NK cells in pancreatic cancer remains poorly defined. Nevertheless, increasing evidence of the importance of NK cells in this dismal prognosis disease is beginning to come to light. Here, we review the role of NK cells in pancreatic cancer, examine the complex interactions of these crucial effector units within pancreatic cancer stroma and shed light on the increasingly attractive use of NK cells as therapy.


Subject(s)
Pancreatic Neoplasms , Humans , Immunotherapy , Killer Cells, Natural , Pancreatic Neoplasms/therapy , Prognosis , Tumor Microenvironment
3.
Curr Opin Immunol ; 57: 46-52, 2019 04.
Article in English | MEDLINE | ID: mdl-30798069

ABSTRACT

Tertiary lymphoid organs named also tertiary lymphoid structures (TLS) often occur at sites of autoimmune inflammation, organ transplantation and cancer. Although the mechanisms for their formation/function are not entirely understood, it is known that TLS can display features of active germinal centres supporting the proliferation and differentiation of (auto)-reactive B cells. In this Review, we discuss current knowledge on TLS-associated B cells with particular reference on how within diseased tissues these structures are linked to either deleterious or protective outcomes in patients and the potential for therapeutic targeting of TLS through novel drugs.


Subject(s)
B-Lymphocytes/immunology , Graft Rejection/immunology , Neoplasms/immunology , Tertiary Lymphoid Structures/immunology , Animals , Autoimmunity , Carcinogenesis , Cell Differentiation , Humans , Lymphatic System , Organ Transplantation , Transplantation Immunology
4.
Eur J Immunol ; 45(9): 2638-49, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26096294

ABSTRACT

Currently little is known as to how nutritionally derived compounds may affect dendritic cell (DC) maturation and potentially prevent inappropriate inflammatory responses that are characteristic of chronic inflammatory syndromes. Previous observations have demonstrated that two polyphenols quercetin and piperine delivered through reconstituted oil bodies (ROBs-QP) can influence DC maturation in response to LPS leading to a modulated inflammatory response. In the present study, we examined the molecular effects of ROBs-QP exposure on DC differentiation in mice and identified a unique molecular signature in response to LPS administration that potentially modulates DC maturation and activity in inflammatory conditions. Following LPS administration, ROBs-QP-exposed DCs expressed an altered molecular profile as compared with control DCs, including cytokine and chemokine production, chemokine receptor repertoire, and antigen presentation ability. In vivo ROBs-QP administration suppresses antigen-specific T-cell division in the draining lymph nodes resulting from a reduced ability to create stable immunological synapse. Our data demonstrate that polyphenols exposure can drive DCs toward a new anti-inflammatory molecular profile capable of dampening the inflammatory response, highlighting their potential as complementary nutritional approaches in the treatment of chronic inflammatory syndromes.


Subject(s)
Alkaloids/pharmacology , Benzodioxoles/pharmacology , Cell Proliferation/drug effects , Dendritic Cells/drug effects , Piperidines/pharmacology , Polyphenols/pharmacology , Polyunsaturated Alkamides/pharmacology , Quercetin/pharmacology , T-Lymphocytes/drug effects , Animals , Antigen Presentation/drug effects , Cell Differentiation/drug effects , Cytokines/genetics , Cytokines/immunology , Dendritic Cells/immunology , Dendritic Cells/pathology , Gene Expression , Inflammation/chemically induced , Inflammation/genetics , Inflammation/immunology , Inflammation/pathology , Lipopolysaccharides , Lymphocyte Activation/drug effects , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Primary Cell Culture , Receptors, Chemokine/genetics , Receptors, Chemokine/immunology , T-Lymphocytes/immunology , T-Lymphocytes/pathology
5.
PLoS One ; 9(2): e88898, 2014.
Article in English | MEDLINE | ID: mdl-24558444

ABSTRACT

Polyphenols are natural compounds capable of interfering with the inflammatory pathways of several in vitro model systems. In this study, we developed a stable and effective strategy to administer polyphenols to treat in vivo models of acute intestinal inflammation. The in vitro suppressive properties of several polyphenols were first tested and compared for dendritic cells (DCs) production of inflammatory cytokines. A combination of the polyphenols, quercetin and piperine, were then encapsulated into reconstituted oil bodies (OBs) in order to increase their stability. Our results showed that administration of low dose reconstituted polyphenol OBs inhibited LPS-mediated inflammatory cytokine secretion, including IL-6, IL-23, and IL-12, while increasing IL-10 and IL-1Rα production. Mice treated with the polyphenol-containing reconstituted OBs (ROBs) were partially protected from dextran sodium sulfate (DSS)-induced colitis and associated weight loss, while mortality and inflammatory scores revealed an overall anti-inflammatory effect that was likely mediated by impaired DC immune responses. Our study indicates that the administration of reconstituted quercetin and piperine-containing OBs may represent an effective and potent anti-inflammatory strategy to treat acute intestinal inflammation.


Subject(s)
Dendritic Cells/drug effects , Intestinal Diseases/drug therapy , Polyphenols/administration & dosage , Polyphenols/pharmacology , Acute Disease , Alkaloids/administration & dosage , Alkaloids/pharmacology , Alkaloids/therapeutic use , Animals , Benzodioxoles/administration & dosage , Benzodioxoles/pharmacology , Benzodioxoles/therapeutic use , Capsules , Colitis/chemically induced , Colitis/drug therapy , Colitis/immunology , Colitis/metabolism , Dendritic Cells/metabolism , Dextran Sulfate/adverse effects , Dose-Response Relationship, Drug , Drug Stability , Inflammation/chemically induced , Inflammation/drug therapy , Inflammation/immunology , Inflammation/metabolism , Interleukin-6/biosynthesis , Intestinal Diseases/chemically induced , Intestinal Diseases/immunology , Intestinal Diseases/metabolism , Lipopolysaccharides/pharmacology , Liposomes , Mice , Peptidoglycan/pharmacology , Piperidines/administration & dosage , Piperidines/pharmacology , Piperidines/therapeutic use , Polyphenols/therapeutic use , Polyunsaturated Alkamides/administration & dosage , Polyunsaturated Alkamides/pharmacology , Polyunsaturated Alkamides/therapeutic use , Quercetin/administration & dosage , Quercetin/pharmacology , Quercetin/therapeutic use , Tumor Necrosis Factor-alpha/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...